Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Dry (Atrophic) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration

The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aciont Inc.

Alimera Sciences, Inc.

Allergan Plc

Apellis Pharmaceuticals Inc

Astellas Pharma Inc.

Benitec Biopharma Limited

Biophytis SAS

Catalyst Biosciences, Inc.

Cell Cure Neurosciences, Ltd.

Charlesson LLC.

Foamix Pharmaceuticals Ltd.

Genentech Inc

GenSight Biologics S.A.

GlaxoSmithKline Plc

Icon Bioscience, Inc.

Inception Sciences, Inc.

Johnson & Johnson

Kodiak Sciences Inc.

MacuCLEAR Inc

MeiraGTx Limited

Novartis AG

Ophthotech Corp.

Orphagen Pharmaceuticals, Inc.

pSivida Corp.

Samumed LLC

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Dry (Atrophic) Macular Degeneration Overview 11

Therapeutics Development 12

Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 12

Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 13

Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 14

Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 16

Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Dry (Atrophic) Macular Degeneration - Products under Development by Companies 21

Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 23

Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 24

Aciont Inc. 24

Alimera Sciences, Inc. 25

Allergan Plc 26

Apellis Pharmaceuticals Inc 27

Astellas Pharma Inc. 28

Benitec Biopharma Limited 29

Biophytis SAS 30

Catalyst Biosciences, Inc. 31

Cell Cure Neurosciences, Ltd. 32

Charlesson LLC. 33

Foamix Pharmaceuticals Ltd. 34

Genentech Inc 35

GenSight Biologics S.A. 36

GlaxoSmithKline Plc 37

Icon Bioscience, Inc. 38

Inception Sciences, Inc. 39

Johnson & Johnson 40

Kodiak Sciences Inc. 41

MacuCLEAR Inc 42

MeiraGTx Limited 43

Novartis AG 44

Ophthotech Corp. 45

Orphagen Pharmaceuticals, Inc. 46

pSivida Corp. 47

Samumed LLC 48

Sucampo Pharmaceuticals, Inc. 49

Sun Pharma Advanced Research Co Ltd 50

Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 54

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

A-005 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

APL-2 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

avacincaptad pegol sodium - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

BBAMD-231 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

BIO-201 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

brimonidine tartrate implant - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CLG-561 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

CLT-005 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

CNTO-2476 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Drug for Age Related Macular Degeneration - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

EG-30 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

FMX-103 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Gene Therapy for Ocular Diseases - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

GS-030 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

GSK-933776 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

ICR-14967 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

KSI-401 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

lampalizumab - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MA09-hRPE - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

MC-1101 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

methotrexate - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

OCU-100 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

ONL-1204 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

OpRegen - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

OpRegen Plus - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

RC-1 Alpha - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

RST-001 - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Small Molecule for Dry AMD and Wet AMD - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

Small Molecules for AMD - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

Small Molecules for Dry Age-Related Macular Degeneration - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Small Molecules for Dry AMD - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

tesidolumab - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

unoprostone isopropyl - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

VM-100 - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

Dry (Atrophic) Macular Degeneration - Dormant Projects 121

Dry (Atrophic) Macular Degeneration - Discontinued Products 124

Dry (Atrophic) Macular Degeneration - Product Development Milestones 125

Featured News & Press Releases 125

Aug 30, 2016: RetroSense Therapeutics Granted Patent on Proprietary Method for Restoring Vision using Optogenetics 125

May 05, 2016: RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences 125

Apr 12, 2016: BIOPHYTIS to Present Pre-Clinical Data on BIO 201 at Upcoming Scientific Conference 126

Nov 17, 2015: Biophytis establishes New subsidiary to accelerate clinical development of Maculia 126

Oct 01, 2013: Roche to present data on Lampalizumab at investor event 127

Aug 27, 2013: Roche’s lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 127

Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 128

May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 129

Apr 15, 2013: ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy 129

Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 130

Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells 131

Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 132

Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone 132

Nov 28, 2012: ACT Completes Higher-Dosage Cohort In Both US Clinical Trials Using Retinal Pigment Epithelial Cells 133

Aug 02, 2012: ACT Announces First Dry Age-Related Macular Degeneration Patient Treated With Higher Dosage Of Embryonic Stem Cell-Derived RPE Cells 134

Appendix 135

Methodology 135

Coverage 135

Secondary Research 135

Primary Research 135

Expert Panel Validation 135

Contact Us 135

Disclaimer 136

List of Tables

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016 12

Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Number of Products under Development by Companies, H2 2016 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Comparative Analysis by Late Stage Development, H2 2016 17

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Development, H2 2016 19

Comparative Analysis by Unknown Stage Development, H2 2016 20

Products under Development by Companies, H2 2016 21

Products under Development by Companies, H2 2016 (Contd..1) 22

Products under Investigation by Universities/Institutes, H2 2016 23

Dry (Atrophic) Macular Degeneration – Pipeline by Aciont Inc., H2 2016 24

Dry (Atrophic) Macular Degeneration – Pipeline by Alimera Sciences, Inc., H2 2016 25

Dry (Atrophic) Macular Degeneration – Pipeline by Allergan Plc, H2 2016 26

Dry (Atrophic) Macular Degeneration – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 27

Dry (Atrophic) Macular Degeneration – Pipeline by Astellas Pharma Inc., H2 2016 28

Dry (Atrophic) Macular Degeneration – Pipeline by Benitec Biopharma Limited, H2 2016 29

Dry (Atrophic) Macular Degeneration – Pipeline by Biophytis SAS, H2 2016 30

Dry (Atrophic) Macular Degeneration – Pipeline by Catalyst Biosciences, Inc., H2 2016 31

Dry (Atrophic) Macular Degeneration – Pipeline by Cell Cure Neurosciences, Ltd., H2 2016 32

Dry (Atrophic) Macular Degeneration – Pipeline by Charlesson LLC., H2 2016 33

Dry (Atrophic) Macular Degeneration – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 34

Dry (Atrophic) Macular Degeneration – Pipeline by Genentech Inc, H2 2016 35

Dry (Atrophic) Macular Degeneration – Pipeline by GenSight Biologics S.A., H2 2016 36

Dry (Atrophic) Macular Degeneration – Pipeline by GlaxoSmithKline Plc, H2 2016 37

Dry (Atrophic) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H2 2016 38

Dry (Atrophic) Macular Degeneration – Pipeline by Inception Sciences, Inc., H2 2016 39

Dry (Atrophic) Macular Degeneration – Pipeline by Johnson & Johnson, H2 2016 40

Dry (Atrophic) Macular Degeneration – Pipeline by Kodiak Sciences Inc., H2 2016 41

Dry (Atrophic) Macular Degeneration – Pipeline by MacuCLEAR Inc, H2 2016 42

Dry (Atrophic) Macular Degeneration – Pipeline by MeiraGTx Limited, H2 2016 43

Dry (Atrophic) Macular Degeneration – Pipeline by Novartis AG, H2 2016 44

Dry (Atrophic) Macular Degeneration – Pipeline by Ophthotech Corp., H2 2016 45

Dry (Atrophic) Macular Degeneration – Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 46

Dry (Atrophic) Macular Degeneration – Pipeline by pSivida Corp., H2 2016 47

Dry (Atrophic) Macular Degeneration – Pipeline by Samumed LLC, H2 2016 48

Dry (Atrophic) Macular Degeneration – Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 49

Dry (Atrophic) Macular Degeneration – Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 50

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Stage and Target, H2 2016 53

Number of Products by Stage and Mechanism of Action, H2 2016 55

Number of Products by Stage and Route of Administration, H2 2016 57

Number of Products by Stage and Molecule Type, H2 2016 59

Dry (Atrophic) Macular Degeneration – Dormant Projects, H2 2016 121

Dry (Atrophic) Macular Degeneration – Dormant Projects (Contd..1), H2 2016 122

Dry (Atrophic) Macular Degeneration – Dormant Projects (Contd..2), H2 2016 123

Dry (Atrophic) Macular Degeneration – Discontinued Products, H2 2016 124

List of Figures

List of Figures

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H2 2016 12

Number of Products under Development for Dry (Atrophic) Macular Degeneration – Comparative Analysis, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 18

Comparative Analysis by Early Stage Products, H2 2016 19

Assessment by Monotherapy Products, H2 2016 51

Number of Products by Top 10 Targets, H2 2016 52

Number of Products by Stage and Top 10 Targets, H2 2016 52

Number of Products by Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 54

Number of Products by Routes of Administration, H2 2016 56

Number of Products by Stage and Routes of Administration, H2 2016 56

Number of Products by Top 10 Molecule Types, H2 2016 58

Number of Products by Stage and Top 10 Molecule Types, H2 2016 58

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports